GoAI
Get started
electroCore, Inc. logo

electroCore, Inc.

ECOR

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$10.52

+$0.31 · +3.04%

Aug 21, 4:00 PM ET

ECOR company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

70

Undervalued

Momentum

38

Weakening

Sentiment

64

Bullish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Thomas J. Errico
Listed since
Jun 22, 2018
Employees
83

Market position

Day range

Current $10.52

52-week range

Current $10.52

Open
$10.63
Previous close
$10.21
Volume
59.94K
0.59× average
Average volume
101.56K
Average daily volume
Market cap
94.85M USD
Beta
0.94
Market reference 1
50-day average
$7.7916
+35.02% above average
200-day average
$6.6644
+57.85% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-6.19×
P/B (TTM)
-35.46×
P/S (TTM)
2.57×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
87.06%
Operating margin
-37.64%
Net margin
-39.96%

Financial health

Debt / equity
-3.43×
Altman Z-score
-13.84
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends132%-50%-231%-413%Gross margin, FY2021: 74.59%Gross margin, FY2022: 81.19%Gross margin, FY2023: 82.51%Gross margin, FY2024: 84.97%Gross margin, FY2025: 86.75%Operating margin, FY2021: -367.69%Operating margin, FY2022: -266.22%Operating margin, FY2023: -117.31%Operating margin, FY2024: -48.30%Operating margin, FY2025: -41.06%Net margin, FY2021: -315.87%Net margin, FY2022: -257.94%Net margin, FY2023: -117.49%Net margin, FY2024: -47.20%Net margin, FY2025: -43.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 74.59%. Gross margin FY2022 81.19%. Gross margin FY2023 82.51%. Gross margin FY2024 84.97%. Gross margin FY2025 86.75%. Operating margin FY2021 -367.69%. Operating margin FY2022 -266.22%. Operating margin FY2023 -117.31%. Operating margin FY2024 -48.30%. Operating margin FY2025 -41.06%. Net margin FY2021 -315.87%. Net margin FY2022 -257.94%. Net margin FY2023 -117.49%. Net margin FY2024 -47.20%. Net margin FY2025 -43.60%.

Income trends

Revenue

32.03M USD+27.20%

Operating income

−13.15M USD-8.15%

Net income

−13.97M USD-17.50%
Income trends across reported periods37.52M USD15.56M USD−6.4M USD−28.36M USDRevenue, FY2021: 5.45M USDRevenue, FY2022: 8.59M USDRevenue, FY2023: 16.03M USDRevenue, FY2024: 25.18M USDRevenue, FY2025: 32.03M USDOperating income, FY2021: −20.04M USDOperating income, FY2022: −22.87M USDOperating income, FY2023: −18.81M USDOperating income, FY2024: −12.16M USDOperating income, FY2025: −13.15M USDNet income, FY2021: −17.22M USDNet income, FY2022: −22.16M USDNet income, FY2023: −18.83M USDNet income, FY2024: −11.89M USDNet income, FY2025: −13.97M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.45M USD. Revenue FY2022 8.59M USD. Revenue FY2023 16.03M USD. Revenue FY2024 25.18M USD. Revenue FY2025 32.03M USD. Operating income FY2021 −20.04M USD. Operating income FY2022 −22.87M USD. Operating income FY2023 −18.81M USD. Operating income FY2024 −12.16M USD. Operating income FY2025 −13.15M USD. Net income FY2021 −17.22M USD. Net income FY2022 −22.16M USD. Net income FY2023 −18.83M USD. Net income FY2024 −11.89M USD. Net income FY2025 −13.97M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue32.03M USD25.18M USD16.03M USD8.59M USD5.45M USD
Cost of goods sold4.24M USD3.79M USD2.8M USD1.62M USD1.39M USD
Gross profit27.79M USD21.4M USD13.23M USD6.98M USD4.07M USD
Research and development2.74M USD2.36M USD5.32M USD5.52M USD2.54M USD
Selling, general, and administrative38.21M USD31.2M USD26.71M USD24.33M USD21.57M USD
Operating expenses40.94M USD33.56M USD32.03M USD29.85M USD24.11M USD
Interest income298K USD572K USD433K USD287K USD11K USD
Interest expense590K USD————
Depreciation and amortization1.68M USD1.26M USD1.26M USD596K USD382K USD
Operating income−13.15M USD−12.16M USD−18.81M USD−22.87M USD−20.04M USD
Net income−13.97M USD−11.89M USD−18.83M USD−22.16M USD−17.22M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.65
FY2025
Latest fiscal-year revenue
32.03M USD
FY2025 · +27.20% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-1.28-2.52-3.76-5FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend34.69M24.06M13.43M2.79MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

6 ratings
Strong buy00%
Buy350%
Hold350%
Sell00%
Strong sell00%

ECOR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ECOR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
856.16K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
State Street SPDR S&P International Small Cap ETF logoState Street SPDR S&P International Small Cap ETFGWX
Market value
477.79K
Weight
0.05%
AUM
927.26M USD
Expense ratio
0.40%
Price / 1D
$46.205+0.40%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
416.23K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
181.68K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research ECOR

research.disclaimer